02-25-02

A

Please type a plus sign (+) inside this box +

Attorney Docket P1007R1C1
PATENT

EV 016 026 884 US: Expr ss Mail Number	February 21 , 2002: Date of Deposit	
Washington, D.C. 20231.	Addressee" service under 37 CFR ressed to "Assistant Commissioner of Patents,	7 TO
<u>Diàne L'Maroc</u> Diane L	Marschang	

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

## NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

This application is for an original, non-provisional application.

Inventor(s) (or Application "Identifier"):

Avi J. Ashkenazi

Title: APO-2LI AND APO-3 POLYPEPTIDES

## 1. Type of Application

[]	This is a non-provisional application claiming priority to provisional application no.	, filed
	, the entire disclosure of which is hereby incorporated by reference.	,

[x] This is a [] continuation-in-part [x] continuation [] divisional application claiming priority to application Serial Number 08/829,270, filed March 31, 1997, the entire disclosure of which is hereby incorporated by reference.

# 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

93 pages of specification

1 pages of abstract

13 sheet(s) of drawings [x] formal [] informal

#### 3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)
An executed declaration of the inventor(s) [] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

#105006

- X A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
- (for Cont./Div. where inventor(s) being deleted)
- A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

## 4. Assignment

(for new and CIP applications)

An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)

x The prior application is assigned of record to Genentech, Inc.

# 5. Amendments (for continuation and divisional applications)

- X Cancel in this application original claims <u>1-25 and 27-45</u> of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
- X A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

# 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

The state point deficition and follows.								
CLAIMS FOR FEE CALCULATION								
Number	Filed	Númb	er Extra	Rate	Basic Fee 37 CFR 1.16(a) \$740.00			
Total Claims	16	- 20 =	0	X \$18.00	\$0.00			
Independent Claims	3	- 3=	0	X \$84.00	\$0.00			
Multiple dependent claim(s), if any			+ \$280.00	\$0.00				
Filing Fee Calculation					\$740.00			

### 7. Method of Payment of Fees

\_X The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$740.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

X The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

## 9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- [x] Submission of "Sequence Listing" (paper copy), and Request to Use Computer Readable Sequence and Certificate re Sequence Listing.
- [] A new Power of Attorney or authorization of agent.
- [] Other:

# 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

A petition, fee and/or response has been filed to extend the term in the pending prior application until

X A copy of the petition for extension of time in the *prior* application is attached.

11. Correspondence Address:

X Address all future communications to:

Attn: Diane L. Marschang

Respectfully submitted, GENENTECH, INC.

Date: February 21, 2002

Diane L. Marschang
Reg. No. 35,600

Telephone No. (650) 225-5416

09157
PATENT TRADEMARK OFFICE

#### Patent Docket P1007R1

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Avi J. Ashkenazi

Serial No.: 08/829,270

Filed: March 31, 1997

For:

APO-2LI AND APO-3 POLYPEPTIDES

Group Art Unit: 1653

Examiner: G. Bugaisky

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231 on

February <u>2/-</u>, 2002

Diane L. Marschang

# PETITION AND FEE FOR FOUR MONTH EXTENSION OF TIME (37 CFR 1.136(a))

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

A Notice of Appeal and Petition to Extend Time, for the above referenced application, was mailed on August 24, 2001 extending the time for response to the Final Office Action dated February 27, 2001 to August 27, 2001. The new time for response is October 24, 2001. Applicant petitions the Commissioner of Patents and Trademarks to extend the time for response for four months from October 24, 2001 to February 24, 2002. The extended time for response does not exceed the statutory period.

Please charge Deposit Account No. 07-0630 in the amount of \$1,440 to cover the cost of the extension. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: February 21, 2002

: Wane of Marschang Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

09157

PATENT TRADEMARK OFFICE

#104905